[tds_menu_login inline="yes" guest_tdicon="td-icon-profile" logout_tdicon="td-icon-log-out" tdc_css="eyJwaG9uZSI6eyJtYXJnaW4tcmlnaHQiOiIyMCIsIm1hcmdpbi1ib3R0b20iOiIwIiwibWFyZ2luLWxlZnQiOiI2IiwiZGlzcGxheSI6IiJ9LCJwaG9uZV9tYXhfd2lkdGgiOjc2N30=" toggle_hide="eyJwaG9uZSI6InllcyJ9" ia_space="eyJwaG9uZSI6IjAifQ==" icon_size="eyJhbGwiOjI0LCJwaG9uZSI6IjIwIn0=" avatar_size="eyJwaG9uZSI6IjIwIn0=" show_menu="yes" menu_offset_top="eyJwaG9uZSI6IjE4In0=" menu_offset_horiz="eyJhbGwiOjgsInBob25lIjoiLTMifQ==" menu_width="eyJwaG9uZSI6IjE4MCJ9" menu_horiz_align="eyJhbGwiOiJjb250ZW50LWhvcml6LWxlZnQiLCJwaG9uZSI6ImNvbnRlbnQtaG9yaXotcmlnaHQifQ==" menu_uh_padd="eyJwaG9uZSI6IjEwcHggMTVweCA4cHgifQ==" menu_gh_padd="eyJwaG9uZSI6IjEwcHggMTVweCA4cHgifQ==" menu_ul_padd="eyJwaG9uZSI6IjhweCAxNXB4In0=" menu_ul_space="eyJwaG9uZSI6IjYifQ==" menu_ulo_padd="eyJwaG9uZSI6IjhweCAxNXB4IDEwcHgifQ==" menu_gc_padd="eyJwaG9uZSI6IjhweCAxNXB4IDEwcHgifQ==" menu_bg="var(--news-hub-black)" menu_shadow_shadow_size="eyJwaG9uZSI6IjAifQ==" menu_arrow_color="rgba(0,0,0,0)" menu_uh_color="var(--news-hub-light-grey)" menu_uh_border_color="var(--news-hub-dark-grey)" menu_ul_link_color="var(--news-hub-white)" menu_ul_link_color_h="var(--news-hub-accent-hover)" menu_ul_sep_color="var(--news-hub-dark-grey)" menu_uf_txt_color="var(--news-hub-white)" menu_uf_txt_color_h="var(--news-hub-accent-hover)" menu_uf_border_color="var(--news-hub-dark-grey)" f_uh_font_size="eyJwaG9uZSI6IjEyIn0=" f_uh_font_line_height="eyJwaG9uZSI6IjEuMyJ9" f_uh_font_family="eyJwaG9uZSI6IjMyNSJ9" f_links_font_size="eyJwaG9uZSI6IjEyIn0=" f_links_font_line_height="eyJwaG9uZSI6IjEuMyJ9" f_links_font_family="eyJwaG9uZSI6IjMyNSJ9" f_uf_font_size="eyJwaG9uZSI6IjEyIn0=" f_uf_font_line_height="eyJwaG9uZSI6IjEuMyJ9" f_uf_font_family="eyJwaG9uZSI6IjMyNSJ9" f_gh_font_family="eyJwaG9uZSI6IjMyNSJ9" f_gh_font_size="eyJwaG9uZSI6IjEyIn0=" f_gh_font_line_height="eyJwaG9uZSI6IjEuMyJ9" f_btn1_font_family="eyJwaG9uZSI6IjMyNSJ9" f_btn1_font_weight="eyJwaG9uZSI6IjcwMCJ9" f_btn1_font_transform="eyJwaG9uZSI6InVwcGVyY2FzZSJ9" f_btn2_font_weight="eyJwaG9uZSI6IjcwMCJ9" f_btn2_font_transform="eyJwaG9uZSI6InVwcGVyY2FzZSJ9" f_btn2_font_family="eyJwaG9uZSI6IjMyNSJ9"]
4.4 C
New York
[tds_menu_login guest_tdicon="td-icon-profile" logout_tdicon="td-icon-log-out" tdc_css="eyJhbGwiOnsibWFyZ2luLWJvdHRvbSI6IjAiLCJkaXNwbGF5IjoiIn19" toggle_txt_color="var(--news-hub-white)" menu_offset_top="eyJhbGwiOiIxOSIsImxhbmRzY2FwZSI6IjE3IiwicG9ydHJhaXQiOiIxNSJ9" menu_offset_horiz="eyJhbGwiOi02LCJsYW5kc2NhcGUiOiItMyIsInBvcnRyYWl0IjoiLTIifQ==" menu_horiz_align="content-horiz-right" menu_bg="var(--news-hub-black)" menu_uh_color="var(--news-hub-light-grey)" menu_uh_border_color="var(--news-hub-dark-grey)" menu_ul_link_color="#ffffff" menu_ul_link_color_h="var(--news-hub-accent-hover)" menu_ul_sep_color="var(--news-hub-dark-grey)" menu_uf_txt_color="var(--news-hub-white)" menu_uf_txt_color_h="var(--news-hub-accent-hover)" menu_uf_border_color="var(--news-hub-dark-grey)" f_uh_font_family="325" f_uh_font_line_height="1.3" f_links_font_family="325" f_links_font_line_height="1.3" f_uf_font_line_height="1.3" f_uf_font_family="325" menu_uh_padd="eyJhbGwiOiIyMHB4IDI1cHggMThweCIsImxhbmRzY2FwZSI6IjE1cHggMjBweCAxM3B4IiwicG9ydHJhaXQiOiIxMHB4IDE1cHggOHB4In0=" menu_ul_padd="eyJhbGwiOiIxOHB4IDI1cHgiLCJsYW5kc2NhcGUiOiIxNnB4IDIwcHgiLCJwb3J0cmFpdCI6IjhweCAxNXB4In0=" menu_ul_space="eyJhbGwiOiIxMCIsImxhbmRzY2FwZSI6IjgiLCJwb3J0cmFpdCI6IjYifQ==" menu_ulo_padd="eyJhbGwiOiIxOHB4IDI1cHggMjBweCIsImxhbmRzY2FwZSI6IjEzcHggMjBweCAxNXB4IiwicG9ydHJhaXQiOiI4cHggMTVweCAxMHB4In0=" menu_shadow_shadow_size="0" menu_arrow_color="rgba(255,255,255,0)" menu_width="eyJhbGwiOiIyMjAiLCJwb3J0cmFpdCI6IjE4MCJ9" show_version="" menu_gh_padd="eyJhbGwiOiIyMHB4IDI1cHggMThweCIsImxhbmRzY2FwZSI6IjE1cHggMjBweCAxM3B4IiwicG9ydHJhaXQiOiIxMHB4IDE1cHggOHB4In0=" menu_gc_padd="eyJhbGwiOiIxOHB4IDI1cHggMjBweCIsImxhbmRzY2FwZSI6IjEzcHggMjBweCAxNXB4IiwicG9ydHJhaXQiOiI4cHggMTVweCAxMHB4In0=" menu_gh_color="var(--news-hub-light-grey)" menu_gh_border_color="var(--news-hub-dark-grey)" f_gh_font_family="325" menu_gc_btn1_bg_color="var(--news-hub-accent)" menu_gc_btn1_bg_color_h="var(--news-hub-accent-hover)" menu_gc_btn2_color="var(--news-hub-accent)" menu_gc_btn2_color_h="var(--news-hub-accent-hover)" f_btn1_font_family="325" f_btn1_font_transform="uppercase" f_btn2_font_family="325" f_btn2_font_transform="uppercase" f_btn1_font_weight="700" f_btn2_font_weight="700" show_menu="yes" f_uf_font_size="eyJsYW5kc2NhcGUiOiIxMiIsInBvcnRyYWl0IjoiMTIifQ==" icon_color="var(--news-hub-white)" icon_size="eyJhbGwiOjIyLCJsYW5kc2NhcGUiOiIyMCIsInBvcnRyYWl0IjoiMTgifQ==" avatar_size="eyJhbGwiOiIyMiIsImxhbmRzY2FwZSI6IjIwIiwicG9ydHJhaXQiOiIxOCJ9" ia_space="eyJhbGwiOiIxMCIsImxhbmRzY2FwZSI6IjgiLCJwb3J0cmFpdCI6IjYifQ==" f_toggle_font_family="325" f_toggle_font_size="eyJhbGwiOiIxNCIsImxhbmRzY2FwZSI6IjEzIiwicG9ydHJhaXQiOiIxMiJ9" logout_size="eyJhbGwiOjE0LCJsYW5kc2NhcGUiOiIxMyJ9" f_uh_font_size="eyJsYW5kc2NhcGUiOiIxMyIsInBvcnRyYWl0IjoiMTIifQ==" f_links_font_size="eyJsYW5kc2NhcGUiOiIxMyIsInBvcnRyYWl0IjoiMTIifQ==" f_gh_font_size="eyJsYW5kc2NhcGUiOiIxMyIsInBvcnRyYWl0IjoiMTIifQ=="]
News

Apple Might Launch Its Own Smart Home Camera As It Focuses On Providing A More Integrated Product Experience For Its Users

Wccftech.com - 0
Apple is increasingly focusing on building its own devices and expanding its ecosystem by taking steps towards a more native experience for users and relying less on third-party accessories. While the Cupertino-based tech giant's HomePod and AppleTV have left quite the mark in the smart home category, it generally relies more on outsourcing cameras and other hardware for smart homes. Now, a new report suggests that the company intends to create a fully integrated experience by developing its own smart home accessories. Gurman hints about Apple working on making smart home products like security cameras for a more integrated experience […]
Deals

Best of Black Friday 2024 – power stations and bundles: Anker SOLIX, Bluetti, EcoFlow, Jackery

9to5Toys.com - 0
We’re continuing our Best of Black Friday posts today with a look at the best current deals on power stations and their respective bundle options. Folks across the country and beyond have been steadily investing more and more in the industry for a vari...
gaming

World Of Warcraft Is Finally Getting Player Homes After 20 Years

Kotaku.com - 0
Blizzard has announced that two decades after its release, World of Warcraft is finally going to let players build a home and live in it. The feature has long been requested by WoW players and now it’s finally coming in the game’s next expansion.Read m...
News

ArenaNet To Release ‘Godspawn’ Update for Guild Wars 2: Janthir Wilds on November 19, Featuring New 50-Player Titan Battle and More

Wccftech.com - 0
Guild Wars 2: Janthir Wilds will receive the Godspawn update, adding a new 50-player boss battle, a new 10-player raid, and a legendary spear. Guild Wars 2: Janthir Wilds is getting the first major update "Godspawn" on November 19th, expanding the story with new story chapters The MMORPG Guild Wars 2 by ArenaNet is receiving its first major update for the Janthir Wilds expansion soon. It's the first of three major updates, and it'll land on November 19. The update will add new content to the game for the players. The Janthir Wilds expansion DLC was released in August this year, […]

Score a 2TB 7,400MB/s Nextorage heatsink SSD compatible with PS5 at $110 low

Classic RTS Games Warcraft and Warcraft 2 Fully Remastered And Out Now

Native Union Classic Apple Watch Strap with soft nubuck leather lining now $20 (Reg. up to $60)

Amazon has ENGWE’s E26 dual suspension all-terrain e-bike hitting a new $849 low (Reg. $1,399)

Hello! Score 50% off Sam’s Club memberships just in time for the holidays at $25 (Reg. $50)

Dragon Age: The Veilguard’s Hardest Choice Has Fans Scouring For A Way Out

Spigen’s Titanium Keychain Multi-tool with knife, bottle opener, and carabiner now $34 (50% off)

NVIDIA’s DLSS 3.8.10 Package Reduces Preset Modes To Just Two Profiles, Drastically Reducing DLL File Size

Xbox Boss Says No ‘Red Line’ With Exclusives, Including Even Halo

PlayStation Store and Xbox gift cards now on sale from $9 ahead of upcoming Black Friday sales

Apple Will Launch A New ‘Command Center’ Home Device In March With Apple Intelligence Integration, As It Steps Into The Home Industry

Heybike’s Cityrun commuter e-bike carries you up to 55 miles of travel on a four-hour charge at $999 low (Save $600), more

Get two fully adjustable foldable smartphone holders on rotating metal bases at just $8 Prime shipped ($4 ea.)

What did the snowball Earth look like?

PlayStation Plus Brings Back Grand Theft Auto V And A Bunch Of Other Big Games

How Valve made Half-Life 2 and set a new standard for future games

Apple’s MetalFX Upscaling Comparison At 1080p Running Resident Evil 4 Remake Shows Reduced Image Quality, But Framerate Gets Up To 44 Percent Performance Bump

Here’s Our Favorite Cosplay From Dragon Con 2024

Nordstrom’s Early Black Friday Sale is live! Save up to 60% off Nike, Cole Haan, On Cloud, more

Latest Bose Ultra Open earbuds with spatialized audio return to $249 Amazon low

News

Drugmaker to testify on why weight-loss drugs cost 15x more in the US

ArsTechnica.com - 0
Bernie Sanders cancels subpoena vote.
Read more
News

Novo Nordisk’s GLP-1 Weight Loss Drug Wegovy Is Not a Panacea for Obesity

Wccftech.com - 0
Novo Nordisk (NYSE: NVO) has added billions of dollars in market capitalization over the ongoing craze around the GLP-1 anti-obesity and anti-diabetes drugs. However, the Danish pharma giant's most recognizable weight loss drug, Wegovy, is increasingly looking like a stepping stone instead of the promised panacea for the obesity pandemic. For the benefit of those who might not be aware, the GLP-1 hormone plays an important role in suppressing hunger and regulating the production of insulin and glucose. After a meal, GLP-1 agonists raise the level of insulin, which decreases blood glucose levels. Simultaneously, these drugs reduce the speed at […]
Read more
News

Cutting-Edge Biotech: A Novel Gene Therapy That Reverses Aging and a New Oral GLP-1 Drug From Viking Therapeutics

Wccftech.com - 0
There is a reason why biotech is considered a very volatile sector. After all, fortunes are made and destroyed within a few seconds in this sphere, dictated by the outcome of clinical trials for experimental therapies. Fortunately, over the past few days, we've received some very encouraging news on two unrelated but equally important vectors for improving the overall quality of human life: a new gene therapy that has the potential to significantly extend the human lifespan and a new oral GLP-1 weight loss drug candidate from Viking Therapeutics (NASDAQ: VKTX). Viking Therapeutics’ Oral GLP-1 Weight Loss Drug Is Out […]
Read more
News

Novo Nordisk’s GLP-1 Weight Loss Drugs Propel Danish Industrial Production to Record Highs

Wccftech.com - 0
The GLP-1 weight loss drug phenomenon has graduated from a largely theoretical solution to the obesity pandemic to a hardcore economic reality with real-world ramifications. Gone are the days when these drugs were posited as merely a single vector in dealing with the worldwide obesity crisis. Instead, the accelerating adoption of GLP-1 drugs is now giving rise to critical commercial tailwinds that are transforming entire economies. For the benefit of those who might not be aware, GLP-1 drugs can induce significant weight loss by suppressing hunger and regulating the production of insulin and glucose. Novo Nordisk uses Semaglutide as its […]
Read more
News

The Penetration of GLP-1 Weight Loss Drugs Declines for the Second Consecutive Month but Analysts Say This Is a Blip

Wccftech.com - 0
If you weren't already aware, GLP-1 weight loss drugs from the likes of Novo Nordisk and Eli Lilly and Company are the biotech sphere's new craze, managing to rope in seasoned analysts who appear to be salivating at the prospect of billions of dollars in additional revenue streams. Yet, the hype seems to have lost some of its patina recently. TD COWEN: “.. surprised to see two months in a row of declines in the number of people who describe themselves as current users of GLP-1s. .. We believe this is a function of capacity constraints .. Penetration rates may […]
Read more
News

Zealand’s Amylin Is the Underdog That Has Dared To Challenge the Might of GLP-1 Weight Loss Drug Heavyweights

Wccftech.com - 0
The market for weight loss drugs is big enough to allow a plethora of competitors to thrive, as per the prevailing thesis. And we are not just talking about GLP-1 agonists from heavyweights such as Novo Nordisk and Eli Lilly and Company but also newer concoctions, including Amylin-based treatment that is being championed by Zealand. However, it is the unusual agility that is being demonstrated by the reigning Goliaths in this sphere that continues to limit the ascendancy of upstarts. As our regular readers would know, we maintain a generally positive view of weight loss treatments that leverage GLP-1 agonists. […]
Read more
News

Novo Nordisk (NVO) Flags “Supply Disruptions” for Its Wegovy GLP-1 Weight Loss Drug Amid Soaring Demand as the FDA Quantifies “Small” Suicide Risk

Wccftech.com - 0
Novo Nordisk is currently plowing billions of dollars into new facilities to satiate the rip-roaring demand for its GLP-1 cocktail Wegovy. Yet, a sizable supply-demand gap persists, prompting the pharma giant to flag the possibility of "supply disruptions" in the near term. To wit, Novo Nordisk has now announced via a supply update that it has resumed the shipments of 1.7 mg dose strength Wegovy GLP-1 cocktail in the US following a "short-term stock-out." Bear in mind that 1.7 and 2.4 mg dose strengths are primarily geared toward weight loss maintenance. However, the company chose to flag the potential for […]
Read more
News

Eli Lilly and Company’s GLP-1 Weight Loss Drug Is Now Available in the US for as Low as $25

Wccftech.com - 0
One of the biggest hurdles to the mass appeal of a new class of GLP-1 weight loss drugs remains their sky-high prices. Insurance coverage, however, is playing a fundamental role in addressing these affordability concerns, with Eli Lilly and Company coming out today with important price updates for those with insurance coverage in the US. Glucagon-Like Peptide-1, or GLP-1 for short, plays an important role in regulating hunger. These drugs stimulate the release of insulin in the pancreas, block the unhelpful release of glucagon after meals to prevent excess glucose from entering the bloodstream, and slow gastric emptying to reduce […]
Read more
News

Will GLP-1 Weight Loss Drugs Allow Airlines to Save Millions of Dollars and Tank the Fast Food Industry? Here are the Numbers So Far

Wccftech.com - 0
GLP-1 weight loss drugs and the ongoing advances in the AI sphere are currently two of the biggest thematic plays that Wall Street is relentlessly championing, facilitating a phenomenal influx of capital in companies that are seen as beneficiaries of the upheaval that the proponents of these nascent technologies argue is just around the proverbial corner. Recently, GLP-1 drugs from the likes of Novo Nordisk (NVO) and Eli Lilly and Company (LLY) have been billed as a blessing in disguise for the airline industry and a harbinger of doom for the fast food sector. Can a single drug really induce […]
Read more
News

GLP-1 Drug War: Obese Patients Are Typically Twice as Likely To Lose 15% Or More of Their Body Weight With Eli Lilly and Company’s...

Wccftech.com - 0
With around $100 billion in annual sales by the end of this decade up for grabs, the GLP-1 drug war for the global waistline is heating up. Around two weeks back, Novo Nordisk created a media spectacle out of a study that claimed its GLP-1 weight loss drug could slash death risk from heart disease by up to 20 percent. This salvo was apparently fired in response to the steeply discounted price at which Eli Lilly and Company began marketing its own GLP-1 drug. Well, today, the American pharma giant is again attacking Novo Nordisk's proverbial front lines, resplendent in […]
Read more
News

Broadside Against Eli Lilly and Company: Novo Nordisk Hypes the 20% Reduction in Death Risk Offered by Its GLP-1 Weight Loss Drug

Wccftech.com - 0
A price war waged by big pharma usually works in the favor of consumers, in the short term at least, or until the victor captures the market and establishes a monopoly. Eli Lilly and Company unveiled its opening gambit earlier this week by pricing its GLP-1 weight loss drug at a substantial discount to a competing offering by Novo Nordisk. The Danish pharmaceutical giant has now responded by hyping up the results of a critical trial. Glucagon-Like Peptide-1, or GLP-1 for short, plays an important role in regulating hunger. This hormone forms the bedrock of Novo Nordisk's Ozempic and Wegovy […]
Read more
News

Here Is Why McDonald’s Will Be Just Fine Even as Anti-Obesity GLP-1 Drugs From Eli Lilly and Novo Nordisk Decimate Demand in the West

Wccftech.com - 0
One man's gain is often another's loss. When it comes to competing thematic plays in the corporate world, however, the magnitude of ensuing gains and losses can be truly mind-boggling. With analysts estimating over $100 billion in annual US sales for t...
Read more

Tag: Novo Nordisk

How To Unlock Every Hero And Weapon Evolution In Vampire Survivors Ode To Castlevania DLC

gaming
Vampire Survivors draws tons of inspiration from Castlevania, so it is no surprise that the new Ode To Castlevania DLC is fantastic. I’m here to guide you through unlocking each Hero and evolving each weapon, because that’s how you’ll end up accessing ...

Overwatch Players, Y’all Lived Like This In 2016?

gaming
I started playing Overwatch in 2019. By the time I was pushing payloads and getting Play of the Game with a well-placed Tactical Visor, a lot of the old hero kits and team compositions that were infamous when the hero shooter launched in 2016 were more...

Drugmaker to testify on why weight-loss drugs cost 15x more in the US

News
Bernie Sanders cancels subpoena vote.

Novo Nordisk’s GLP-1 Weight Loss Drug Wegovy Is Not a Panacea for Obesity

News
Novo Nordisk (NYSE: NVO) has added billions of dollars in market capitalization over the ongoing craze around the GLP-1 anti-obesity and anti-diabetes drugs. However, the Danish pharma giant's most recognizable weight loss drug, Wegovy, is increasingly looking like a stepping stone instead of the promised panacea for the obesity pandemic. For the benefit of those who might not be aware, the GLP-1 hormone plays an important role in suppressing hunger and regulating the production of insulin and glucose. After a meal, GLP-1 agonists raise the level of insulin, which decreases blood glucose levels. Simultaneously, these drugs reduce the speed at […]

Cutting-Edge Biotech: A Novel Gene Therapy That Reverses Aging and a New Oral GLP-1 Drug From Viking Therapeutics

News
There is a reason why biotech is considered a very volatile sector. After all, fortunes are made and destroyed within a few seconds in this sphere, dictated by the outcome of clinical trials for experimental therapies. Fortunately, over the past few days, we've received some very encouraging news on two unrelated but equally important vectors for improving the overall quality of human life: a new gene therapy that has the potential to significantly extend the human lifespan and a new oral GLP-1 weight loss drug candidate from Viking Therapeutics (NASDAQ: VKTX). Viking Therapeutics’ Oral GLP-1 Weight Loss Drug Is Out […]

Novo Nordisk’s GLP-1 Weight Loss Drugs Propel Danish Industrial Production to Record Highs

News
The GLP-1 weight loss drug phenomenon has graduated from a largely theoretical solution to the obesity pandemic to a hardcore economic reality with real-world ramifications. Gone are the days when these drugs were posited as merely a single vector in dealing with the worldwide obesity crisis. Instead, the accelerating adoption of GLP-1 drugs is now giving rise to critical commercial tailwinds that are transforming entire economies. For the benefit of those who might not be aware, GLP-1 drugs can induce significant weight loss by suppressing hunger and regulating the production of insulin and glucose. Novo Nordisk uses Semaglutide as its […]

The Penetration of GLP-1 Weight Loss Drugs Declines for the Second Consecutive Month but Analysts Say This Is a Blip

News
If you weren't already aware, GLP-1 weight loss drugs from the likes of Novo Nordisk and Eli Lilly and Company are the biotech sphere's new craze, managing to rope in seasoned analysts who appear to be salivating at the prospect of billions of dollars in additional revenue streams. Yet, the hype seems to have lost some of its patina recently. TD COWEN: “.. surprised to see two months in a row of declines in the number of people who describe themselves as current users of GLP-1s. .. We believe this is a function of capacity constraints .. Penetration rates may […]

Zealand’s Amylin Is the Underdog That Has Dared To Challenge the Might of GLP-1 Weight Loss Drug Heavyweights

News
The market for weight loss drugs is big enough to allow a plethora of competitors to thrive, as per the prevailing thesis. And we are not just talking about GLP-1 agonists from heavyweights such as Novo Nordisk and Eli Lilly and Company but also newer concoctions, including Amylin-based treatment that is being championed by Zealand. However, it is the unusual agility that is being demonstrated by the reigning Goliaths in this sphere that continues to limit the ascendancy of upstarts. As our regular readers would know, we maintain a generally positive view of weight loss treatments that leverage GLP-1 agonists. […]

Novo Nordisk (NVO) Flags “Supply Disruptions” for Its Wegovy GLP-1 Weight Loss Drug Amid Soaring Demand as the FDA Quantifies “Small” Suicide Risk

News
Novo Nordisk is currently plowing billions of dollars into new facilities to satiate the rip-roaring demand for its GLP-1 cocktail Wegovy. Yet, a sizable supply-demand gap persists, prompting the pharma giant to flag the possibility of "supply disruptions" in the near term. To wit, Novo Nordisk has now announced via a supply update that it has resumed the shipments of 1.7 mg dose strength Wegovy GLP-1 cocktail in the US following a "short-term stock-out." Bear in mind that 1.7 and 2.4 mg dose strengths are primarily geared toward weight loss maintenance. However, the company chose to flag the potential for […]

Eli Lilly and Company’s GLP-1 Weight Loss Drug Is Now Available in the US for as Low as $25

News
One of the biggest hurdles to the mass appeal of a new class of GLP-1 weight loss drugs remains their sky-high prices. Insurance coverage, however, is playing a fundamental role in addressing these affordability concerns, with Eli Lilly and Company coming out today with important price updates for those with insurance coverage in the US. Glucagon-Like Peptide-1, or GLP-1 for short, plays an important role in regulating hunger. These drugs stimulate the release of insulin in the pancreas, block the unhelpful release of glucagon after meals to prevent excess glucose from entering the bloodstream, and slow gastric emptying to reduce […]

Will GLP-1 Weight Loss Drugs Allow Airlines to Save Millions of Dollars and Tank the Fast Food Industry? Here are the Numbers So Far

News
GLP-1 weight loss drugs and the ongoing advances in the AI sphere are currently two of the biggest thematic plays that Wall Street is relentlessly championing, facilitating a phenomenal influx of capital in companies that are seen as beneficiaries of the upheaval that the proponents of these nascent technologies argue is just around the proverbial corner. Recently, GLP-1 drugs from the likes of Novo Nordisk (NVO) and Eli Lilly and Company (LLY) have been billed as a blessing in disguise for the airline industry and a harbinger of doom for the fast food sector. Can a single drug really induce […]

GLP-1 Drug War: Obese Patients Are Typically Twice as Likely To Lose 15% Or More of Their Body Weight With Eli Lilly and Company’s...

News
With around $100 billion in annual sales by the end of this decade up for grabs, the GLP-1 drug war for the global waistline is heating up. Around two weeks back, Novo Nordisk created a media spectacle out of a study that claimed its GLP-1 weight loss drug could slash death risk from heart disease by up to 20 percent. This salvo was apparently fired in response to the steeply discounted price at which Eli Lilly and Company began marketing its own GLP-1 drug. Well, today, the American pharma giant is again attacking Novo Nordisk's proverbial front lines, resplendent in […]

Broadside Against Eli Lilly and Company: Novo Nordisk Hypes the 20% Reduction in Death Risk Offered by Its GLP-1 Weight Loss Drug

News
A price war waged by big pharma usually works in the favor of consumers, in the short term at least, or until the victor captures the market and establishes a monopoly. Eli Lilly and Company unveiled its opening gambit earlier this week by pricing its GLP-1 weight loss drug at a substantial discount to a competing offering by Novo Nordisk. The Danish pharmaceutical giant has now responded by hyping up the results of a critical trial. Glucagon-Like Peptide-1, or GLP-1 for short, plays an important role in regulating hunger. This hormone forms the bedrock of Novo Nordisk's Ozempic and Wegovy […]

Here Is Why McDonald’s Will Be Just Fine Even as Anti-Obesity GLP-1 Drugs From Eli Lilly and Novo Nordisk Decimate Demand in the West

News
One man's gain is often another's loss. When it comes to competing thematic plays in the corporate world, however, the magnitude of ensuing gains and losses can be truly mind-boggling. With analysts estimating over $100 billion in annual US sales for t...
12Page 1 of 2

Recent articles

spot_img

©Patti.tech 2022